Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06215950 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Name: A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer — clinical trial record (NCT06215950)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2024-01-10

View on ClinicalTrials.gov ↗

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Ovarian Cancer

1,239 trials monitored

See 74 trials at risk

Cervical Cancer

853 trials monitored

See 46 trials at risk

This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic Gynecologic Cancer, and obtain recommended doses and infusion patterns.

Trial Details

NCT Number	NCT06215950
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer, Gynecologic Cancer
Enrollment	36 participants
Start Date	2024-01-10
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-01-22